Articles published by TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
September 28, 2023
Via GlobeNewswire
Tickers
RNAZ

TransCode Therapeutics Announces Pricing of $8 Million Public Offering
September 25, 2023
Via GlobeNewswire
Tickers
RNAZ



TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
August 14, 2023
Via GlobeNewswire
Tickers
RNAZ




Via GlobeNewswire
Tickers
RNAZ

Via GlobeNewswire
Tickers
RNAZ


Via GlobeNewswire
Tickers
RNAZ

TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
April 27, 2023
Via GlobeNewswire
Tickers
RNAZ

Via GlobeNewswire
Tickers
RNAZ


Via GlobeNewswire
Tickers
RNAZ




Via GlobeNewswire
Tickers
RNAZ






TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
December 29, 2022
Via GlobeNewswire
Tickers
RNAZ

TransCode Therapeutics Announces Withdrawal of Registration Statement
December 06, 2022
Via GlobeNewswire
Tickers
RNAZ


TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
November 14, 2022
Via GlobeNewswire
Tickers
RNAZ
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.